Isomorphic Labs Raises $2.1B for AI Drug Discovery Platform

Isomorphic Labs, the AI drug discovery company founded by DeepMind's Demis Hassabis, has secured $2.1 billion in Series B funding. Thrive Capital led the round, which also included Alphabet, GV, MGX, Temasek, CapitalG, and the U.K. government’s AI fund.

The company is developing an AI system called IsoDDE that designs drug molecules from scratch, predicting atomic-level interactions with biological targets. The core technology is AlphaFold 3, the Nobel Prize-winning protein folding model.

The funds will be used to refine the IsoDDE platform and advance the company's drug pipeline toward clinical trials. Hassabis has stated the goal is to build a scalable drug design engine capable of addressing all diseases.

While the technology is promising, Isomorphic Labs has no approved drugs. The gap between computational prediction and clinical reality has challenged many AI biotech companies. The real test will come when the pipeline enters human trials.